MarketCap
Facebook
X
Telegram
argenx SE Net Income | ARGX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income argenx SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 833 M | -295 M | -710 M | -408 M | -529 M | -163 M | -66.6 M | -28.1 M | -21.4 M | -15.3 M | -10.3 M | -6.13 M | -9.7 M | -3.46 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -710 M | -9.38 M |
Quarterly Net Income argenx SE
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 415 M | 833 M | -32.5 M | -295 M | -123 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | -295 M | 348 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ardelyx
ARDX
|
-62 M | $ 3.04 | -1.46 % | $ 733 M |  USA |
 |
Arvinas
ARVN
|
-81 M | $ 7.27 | -0.48 % | $ 515 M | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 144.49 | -0.38 % | $ 7.19 B | USA |
 |
Heat Biologics, Inc.
HTBX
|
-26 M | - | -5.76 % | $ 99.8 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
-21.8 M | - | 0.11 % | $ 419 M | USA |
 |
BioNTech SE
BNTX
|
-1.14 B | $ 87.06 | -1.2 % | $ 21 B |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-12.1 M | $ 2.08 | -0.48 % | $ 13.3 B |  Australia |
 |
Shineco, Inc.
TYHT
|
-6.63 M | - | -3.90 % | $ 97.2 M |  China |
 |
Actinium Pharmaceuticals
ATNM
|
-33.9 M | $ 1.39 | -8.25 % | $ 43.4 M | USA |
 |
Aytu BioScience
AYTU
|
-14.3 M | $ 1.94 | 2.11 % | $ 23.9 M | USA |
 |
Codexis
CDXS
|
-44 M | $ 1.3 | 1.17 % | $ 113 M | USA |
 |
Intec Pharma Ltd
NTEC
|
-14.1 M | - | -12.45 % | $ 17.7 M |  Israel |
 |
Genmab A/S
GMAB
|
7.84 B | $ 44.61 | 1.87 % | $ 2.89 B |  Danmark |
 |
GeoVax Labs
GOVX
|
-21.5 M | $ 0.2 | -5.34 % | $ 192 K | USA |
 |
Cellectar Biosciences
CLRB
|
-21.8 M | $ 1.25 | 2.87 % | $ 3.26 M | USA |
 |
Galectin Therapeutics
GALT
|
-30.8 M | $ 3.23 | 1.1 % | $ 206 M | USA |
 |
GT Biopharma
GTBP
|
-28.4 M | $ 5.28 | -3.3 % | $ 29.1 M | USA |
 |
Progenity, Inc.
PROG
|
-193 M | - | -3.47 % | $ 164 M | USA |
 |
Genprex
GNPX
|
-16.2 M | $ 1.81 | 0.55 % | $ 1.69 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
-45.1 M | - | 1.52 % | $ 136 M | USA |
 |
Cue Biopharma
CUE
|
-26.6 M | $ 18.43 | -1.23 % | $ 1.75 B | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
-16.3 M | - | -1.19 % | $ 28.7 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
-32.8 M | $ 8.78 | 0.69 % | $ 412 M | USA |
 |
Cardiff Oncology
CRDF
|
-45.9 K | $ 0.83 | -8.96 % | $ 55.5 M | USA |
 |
Inhibrx
INBX
|
-241 M | $ 88.68 | -5.03 % | $ 4.18 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-20.7 M | $ 7.7 | -1.41 % | $ 117 M | Australia |
 |
Fate Therapeutics
FATE
|
-136 M | $ 2.06 | -2.37 % | $ 245 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.6 M | $ 50.94 | 1.88 % | $ 1.37 B | USA |
 |
Fulcrum Therapeutics
FULC
|
-74.9 M | $ 3.65 | -0.81 % | $ 231 M | USA |
 |
Hutchison China MediTech Limited
HCM
|
457 M | $ 14.3 | -0.42 % | $ 12.3 B | China |
 |
IDEAYA Biosciences
IDYA
|
-114 M | $ 33.05 | -4.78 % | $ 2.92 B | USA |
 |
InflaRx N.V.
IFRX
|
-45.6 M | $ 1.59 | 1.6 % | $ 107 M | Germany |
 |
Immutep Limited
IMMP
|
-61.4 M | $ 3.07 | -4.22 % | $ 4.47 B | Australia |
 |
Kala Pharmaceuticals
KALA
|
-27 M | $ 0.18 | -3.52 % | $ 1.47 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
-164 M | $ 0.28 | 0.25 % | $ 223 M |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
59 M | $ 71.55 | -6.75 % | $ 5.31 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-196 M | $ 0.46 | -10.55 % | $ 5.03 K | USA |
 |
MediciNova
MNOV
|
12 M | $ 1.4 | 0.72 % | $ 68.7 M | USA |
 |
Seres Therapeutics
MCRB
|
5.7 M | $ 2.02 | -3.35 % | $ 17.9 M | USA |
 |
MediWound Ltd.
MDWD
|
-9.2 M | $ 11.99 | -0.08 % | $ 326 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-26.9 M | $ 11.55 | 0.1 % | $ 1.26 B | USA |
 |
Precigen
PGEN
|
-251 M | $ 6.13 | -0.97 % | $ 1.92 B | USA |
 |
PolyPid Ltd.
PYPD
|
-34.2 M | $ 5.25 | -0.76 % | $ 85.8 M | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.28 | -0.66 % | $ 253 M | USA |
 |
Avidity Biosciences
RNA
|
-685 M | $ 8.03 | -2.07 % | $ 1.11 B | USA |
 |
Summit Therapeutics
SMMT
|
-1.08 B | $ 14.61 | -5.59 % | $ 10.9 B | Britain |
 |
Celsion Corporation
CLSN
|
14.5 M | - | -6.63 % | $ 13.9 M | USA |